Abstract:Semi-quantitative assessment of right ventricular function in comparison to a 3D volumetric approach: A cardiovascular magnetic resonance study Abstract Right ventricular (RV) volume measurements with cardiovascular magnetic resonance (CMR) is considered the gold standard, but acquisition and analysis remain timeconsuming. The aim of our study was therefore to investigate the accuracy and performance of a semi-quantitative assessment of RV function in CMR, compared to the standard quantitative approach. Sevent… Show more
“…TAPSE measurement disregards RV dimensions and is less sensitive to subtle RV changes (14). This is an important limitation to relying on TAPSE alone to assess treatment response.…”
Section: Discussionmentioning
confidence: 99%
“…However, TAPSE assessment maybe insensitive to global RV performance and is confounded by paradoxical interventricular septal motion, and particularly following SAVR, thoracic wall pericardial adhesions. Furthermore, TAPSE is an insensitive marker of RVEF unless it falls below 35% (14). Even 3D echo can systematically underestimate RV volumes (15), such that CMR is considered the reference investigation for RV morphological and functional assessment.…”
Objective: The response of the RV following treatment of aortic stenosis is poorly defined, reflecting the challenge of accurate RV assessment. Cardiovascular magnetic resonance (CMR) is the established reference for imaging of RV volumes, mass and function. We sought to define the impact of transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) upon RV function in patients treated for severe aortic stenosis using CMR.Methods: A 1.5T CMR scan was performed preoperatively and 6 months postoperatively in 112 (56 TAVI, 56 SAVR; 76±8 years) high-risk severe symptomatic aortic stenosis patients across two UK cardiothoracic centres.Results: TAVI patients were older (80.4±6.7 vs. 72.8±7.2 years, p<0.05) with a higher STS score (2.13 ± 0.73 vs. 5.54 ± 3.41%, p< 0.001). At 6 months, SAVR was associated with a significant increase in RV end systolic volume (33±10 vs. 37±10ml/m 2 , p=0.008), and decrease in RV ejection fraction (58±8 vs. 53±8%, p=0.005) and tricuspid annular plane systolic excursion (22±5 vs. 14±3mm, p<0.001). Only 4 (7%) SAVR patients had new RV late gadolinium hyper-enhancement with no new cases seen in the TAVI patients at 6 months.Longer surgical cross-clamp time was the only predictor of increased RV end systolic volume at 6 months. Post-TAVI, there was no observed change in RV volumes or function. Over a maximum 6.3 year follow-up, 18(32%) of TAVI patients and 1(1.7%) of SAVR patients had died (p=0.001). On multivariable Cox analysis, the RV mass at 6m post-TAVI was independently associated with all-cause mortality (HR 1.359, 95% CI 1.108-1.666, p=0.003).
Conclusions: SAVR results in a deterioration
“…TAPSE measurement disregards RV dimensions and is less sensitive to subtle RV changes (14). This is an important limitation to relying on TAPSE alone to assess treatment response.…”
Section: Discussionmentioning
confidence: 99%
“…However, TAPSE assessment maybe insensitive to global RV performance and is confounded by paradoxical interventricular septal motion, and particularly following SAVR, thoracic wall pericardial adhesions. Furthermore, TAPSE is an insensitive marker of RVEF unless it falls below 35% (14). Even 3D echo can systematically underestimate RV volumes (15), such that CMR is considered the reference investigation for RV morphological and functional assessment.…”
Objective: The response of the RV following treatment of aortic stenosis is poorly defined, reflecting the challenge of accurate RV assessment. Cardiovascular magnetic resonance (CMR) is the established reference for imaging of RV volumes, mass and function. We sought to define the impact of transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) upon RV function in patients treated for severe aortic stenosis using CMR.Methods: A 1.5T CMR scan was performed preoperatively and 6 months postoperatively in 112 (56 TAVI, 56 SAVR; 76±8 years) high-risk severe symptomatic aortic stenosis patients across two UK cardiothoracic centres.Results: TAVI patients were older (80.4±6.7 vs. 72.8±7.2 years, p<0.05) with a higher STS score (2.13 ± 0.73 vs. 5.54 ± 3.41%, p< 0.001). At 6 months, SAVR was associated with a significant increase in RV end systolic volume (33±10 vs. 37±10ml/m 2 , p=0.008), and decrease in RV ejection fraction (58±8 vs. 53±8%, p=0.005) and tricuspid annular plane systolic excursion (22±5 vs. 14±3mm, p<0.001). Only 4 (7%) SAVR patients had new RV late gadolinium hyper-enhancement with no new cases seen in the TAVI patients at 6 months.Longer surgical cross-clamp time was the only predictor of increased RV end systolic volume at 6 months. Post-TAVI, there was no observed change in RV volumes or function. Over a maximum 6.3 year follow-up, 18(32%) of TAVI patients and 1(1.7%) of SAVR patients had died (p=0.001). On multivariable Cox analysis, the RV mass at 6m post-TAVI was independently associated with all-cause mortality (HR 1.359, 95% CI 1.108-1.666, p=0.003).
Conclusions: SAVR results in a deterioration
“…TAPSE and RVFAC were initially described in echocardiography with conflicting results according to various studies [18][19][20][21][22]. More recently, TAPSE and RVFS were also evaluated with cardiac MRI in a few studies [23,24] but to date, no cardiac MRI study has evaluated the interest of RVFAC compared with TAPSE and RVFS. Moreover, the reproducibility of these SQt methods and particularly the effect of observers' experience were not clearly reported.…”
“…Left atrial systolic area (LA-SA) was significantly larger in patients from the SDB group compared with the no-SDB group both at baseline (18 …”
Section: Left Atrial Parametersmentioning
confidence: 93%
“…Both insertion points were then transferred to a single four-chamber view in order to calculate the distance of these two points in respect to each other in centimetres. TAPSE can be interpreted as a semi-quantitative evaluation of RVEF overall [18]. RV infarct size was assessed manually using planimetry on short-axis slices, delineating hyper-enhanced areas.…”
Structural and functional integrity of the right heart is important in the prognosis after acute myocardial infarction (AMI). The objective of this study was to assess the impact of sleep disordered breathing (SDB) on structure and function of the right heart early after AMI.54 patients underwent cardiovascular magnetic resonance 3-5 days and 12 weeks after AMI, and were stratified according to the presence of SDB, defined as an apnoea-hypopnoea index of ≥15 events·h −1 . 12 weeks after AMI, end-diastolic volume of the right ventricle had increased significantly in patients with SDB (n=27) versus those without (n=25) (mean±SD 14±23% versus 0±17%, p=0.020). Multivariable linear regression analysis accounting for age, sex, body mass index, smoking, left ventricular mass and left ventricular end-systolic volume showed that the apnoea-hypopnoea index was significantly associated with right ventricular end-diastolic volume (B-coefficient 0.315 (95% CI 0.013-0.617); p=0.041). From baseline to 12 weeks, right atrial diastolic area increased more in patients with SDB (2.9±3.7 cm 2 versus 1.0±2.4 cm 2 , p=0.038; when adjusted for left ventricular end systolic volume, p=0.166).SDB diagnosed shortly after AMI predicts an increase of right ventricular end-diastolic volume and possibly right atrial area within the following 12 weeks. Thus, SDB may contribute to enlargement of the right heart after AMI. @ERSpublications Sleep disordered breathing may predispose to enlargement of the right heart after acute myocardial infarction http://ow.ly/Cc6vv
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.